Skip to main content

Table 4 The efficacy analysis based on the response status to platinum-based chemotherapy

From: Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer

 

Intention-to-treat population (N = 115)

Per-protocol population (N = 92a)

 

Platinum-refractory (N = 36)

Platinum-resistant (N = 31)

Partial platinum-sensitive (N = 48)

Platinum-refractory (N = 25)

platinum-resistant (N = 26)

Partially platinum-sensitive (N = 41)

Complete remission, No. (%)

0, (0.0%)

0, (0.0%)

2, (4.2%)

0, (0.0%)

0, (0.0%)

2, (4.9%)

Partial remission, No. (%)

6, (16.7%)

14, (45.2%)

21, (43.8%)

6, (24.0%)

14, (53.8%)

21, (51.2%)

Stable disease, No. (%)

14, (38.9%)

6, (19.4%)

12, (25.0%)

14, (56.0%)

6, (23.1%)

12, (29.3%)

Disease progression, No. (%)

5, (13.9%)

6, (19.4%)

6, (12.5%)

5, (20.0%)

6, (23.1%)

6, (14.6%)

ORRb, (95%CI)

16.7% (3.9–29.5%)

45.2% (26.6–63.7%)

47.9% (33.3–62.6%)

24.0% (6.0–42.0%)

53.8% (33.3–74.4%)

56.1% (40.2–72.0%)

DCRc, (95%CI)

55.6% (38.5–72.6%)

64.5% (46.7–82.4%)

72.9% (59.9–86.0%)

80.0% (63.1–96.9%)

76.9% (59.6–94.3%)

85.4%(74.1–96.7%)

  1. ORR Objective response rate, DCR Disease control rate; a Fourteen patients receiving less than 2 cycles of PLD and 7 patients without efficacy assessments after 2 cycles of PLD were excluded. Moreover,2 patients had a postbaseline efficacy assessment that could not be confirmed and thus were excluded; b Including patients with complete and partial responses; c Including patients with complete and partial responses and stable disease